PT1463735E - Imidazo-2,1-b-1,3,4-tiadiazol sulfonamidas - Google Patents

Imidazo-2,1-b-1,3,4-tiadiazol sulfonamidas Download PDF

Info

Publication number: PT1463735E
Authority: PT; Portugal
Prior art keywords: imidazo; formula; sulfonamides; thiadiazole; thiadiazole sulfonamides
Prior art date: 2001-12-14

Application number

PT02784979T

Other languages

English (en)

Inventor

John W Gillard

James B Jaquith

Gerald Villeneuve

Alain Boudreault

Stephen Morris

Jon Durkin

Kimberly Hewitt

Nicholas H Marsh

Original Assignee

Aegera Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-14

Filing date

2002-12-16

Publication date

2009-10-15

2002-12-16 Application filed by Aegera Therapeutics Inc filed Critical Aegera Therapeutics Inc

2009-10-15 Publication of PT1463735E publication Critical patent/PT1463735E/pt

Links

229940124530 sulfonamide Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
210000003169 central nervous system Anatomy 0.000 abstract 1
230000001537 neural effect Effects 0.000 abstract 1
239000004090 neuroprotective agent Substances 0.000 abstract 1
210000001428 peripheral nervous system Anatomy 0.000 abstract 1
0 CC=C(**(C1)=CC(c2ccc(C)cc2)=CN1N)[N+](*)([O-])O Chemical compound CC=C(**(C1)=CC(c2ccc(C)cc2)=CN1N)[N+](*)([O-])O 0.000 description 17

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Virology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Psychology (AREA)
Hematology (AREA)
Biotechnology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Orthopedic Medicine & Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Toxicology (AREA)

PT02784979T 2001-12-14 2002-12-16 Imidazo-2,1-b-1,3,4-tiadiazol sulfonamidas PT1463735E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA002364985A CA2364985A1 (en)	2001-12-14	2001-12-14	Imidazo(2,1-b)thiadiazole sulfonamides

Publications (1)

Publication Number	Publication Date
PT1463735E true PT1463735E (pt)	2009-10-15

Family

ID=4170835

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT02784979T PT1463735E (pt)	2001-12-14	2002-12-16	Imidazo-2,1-b-1,3,4-tiadiazol sulfonamidas

Country Status (11)

Country	Link
US (8)	US7230019B2 (pt)
EP (1)	EP1463735B1 (pt)
JP (2)	JP2005519882A (pt)
AT (1)	ATE439363T1 (pt)
AU (1)	AU2002350333B2 (pt)
CA (1)	CA2364985A1 (pt)
DE (1)	DE60233350D1 (pt)
DK (1)	DK1463735T3 (pt)
ES (1)	ES2329882T3 (pt)
PT (1)	PT1463735E (pt)
WO (1)	WO2003051890A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2364985A1 (en) *	2001-12-14	2003-06-14	John W. Gillard	Imidazo(2,1-b)thiadiazole sulfonamides
WO2004111060A1 (en) *	2003-06-13	2004-12-23	Aegera Therapeutics Inc.	IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE SULFOXIDES AND SULFONES
EP1636242A1 (en) *	2003-06-13	2006-03-22	Aegera Therapeutics Inc.	Acylated imidazo (2,1-b) -1,3,4,-thiadia zole-2-sulfonamides, and uses thereof
WO2007034278A2 (en) *	2005-09-19	2007-03-29	Pfizer Products Inc.	Fused imidazole derivatives as c3a receptor antagonists
US20090179638A1 (en) *	2006-02-01	2009-07-16	Aegera Therapeutics Inc.	Assay for identifying inhibitors of neuronal apoptotic pathways
AU2008209320B2 (en) *	2007-01-25	2013-05-30	NAIA Metabolic, Inc.	Insulin sensitisers and methods of treatment
EP2193133B1 (en) *	2007-09-27	2015-08-19	Fundación Centro Nacional de Investigaciones Oncológicas Carlos III	Imidazolothiadiazoles for use as protein kinase inhibitors
ES2548571T3 (es)	2009-04-02	2015-10-19	Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii	Derivados de imidazo[2,1-b][1,3,4]tiadiazol
US8771324B2 (en)	2011-05-27	2014-07-08	Globus Medical, Inc.	Securing fasteners
EP2855489B1 (en)	2012-04-26	2017-01-04	Bristol-Myers Squibb Company	Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
EA201491967A1 (ru)	2012-04-26	2015-03-31	Бристол-Майерс Сквибб Компани	Производные имидазотиадиазола в качестве ингибиторов активируемых протеазой рецепторов 4 (par4) для лечения агрегации тромбоцитов
SMT201700457T1 (it)	2012-04-26	2017-11-15	Bristol Myers Squibb Co	DERlVATI IMIDAZOTIADIAZOLICI E IMIDAZOPIRAZINICI COME INIBITORI DEL RECETTORE ATTIVATO DA PROTEASI 4 (PAR4) PER IL TRATTAMENTO DELL'AGGREGAZIONE PIASTRINICA
EP3053908B1 (en) *	2013-09-30	2018-12-19	FUJIFILM Corporation	Method for producing alpha-halogenoacetophenon compound, and alpha-bromoacetophenon compound
US9598419B1 (en)	2014-06-24	2017-03-21	Universite De Montreal	Imidazotriazine and imidazodiazine compounds
US9617279B1 (en)	2014-06-24	2017-04-11	Bristol-Myers Squibb Company	Imidazooxadiazole compounds
WO2017184520A1 (en) *	2016-04-18	2017-10-26	Vanderbilt University	Substituted and fused 6-membered protease activated receptor 4 (par-4) antagonists
KR20210052435A (ko)	2018-08-30	2021-05-10	니혼 메디피직스 가부시키가이샤	방사성 이미다조티아디아졸 유도체 화합물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US52514A (en) *		1866-02-13		Stove-pipe damper
GB1464259A (en) *	1975-10-03	1977-02-09	Pfizer Ltd	Imidazo-thiazole and -thiadiazole sulphonamides and their use as therapeutic agents
US5604202A (en) *	1990-11-13	1997-02-18	Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University	Use of NGF growth factors to treat drug-induced neuropathy
WO1999062880A1 (en)	1998-06-03	1999-12-09	Gpi Nil Holdings, Inc.	N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
CA2364985A1 (en) *	2001-12-14	2003-06-14	John W. Gillard	Imidazo(2,1-b)thiadiazole sulfonamides
CA2379375A1 (en) *	2002-03-28	2003-09-28	Apotex Inc.	Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases

2001
- 2001-12-14 CA CA002364985A patent/CA2364985A1/en not_active Abandoned
2002
- 2002-12-16 EP EP02784979A patent/EP1463735B1/en not_active Expired - Lifetime
- 2002-12-16 DE DE60233350T patent/DE60233350D1/de not_active Expired - Lifetime
- 2002-12-16 ES ES02784979T patent/ES2329882T3/es not_active Expired - Lifetime
- 2002-12-16 DK DK02784979T patent/DK1463735T3/da active
- 2002-12-16 WO PCT/CA2002/001942 patent/WO2003051890A1/en not_active Ceased
- 2002-12-16 AU AU2002350333A patent/AU2002350333B2/en not_active Ceased
- 2002-12-16 JP JP2003552772A patent/JP2005519882A/ja active Pending
- 2002-12-16 US US10/498,548 patent/US7230019B2/en not_active Expired - Fee Related
- 2002-12-16 AT AT02784979T patent/ATE439363T1/de not_active IP Right Cessation
- 2002-12-16 PT PT02784979T patent/PT1463735E/pt unknown
2006
- 2006-04-05 US US11/399,010 patent/US7741349B2/en not_active Expired - Fee Related
- 2006-04-06 US US11/398,806 patent/US20070021416A1/en not_active Abandoned
- 2006-04-06 US US11/399,033 patent/US7772260B2/en not_active Expired - Fee Related
2007
- 2007-05-07 US US11/797,665 patent/US7700635B2/en not_active Expired - Fee Related
- 2007-05-07 US US11/797,664 patent/US20070238768A1/en not_active Abandoned
- 2007-05-07 US US11/797,663 patent/US7714003B2/en not_active Expired - Fee Related
2008
- 2008-04-07 US US12/099,123 patent/US20090042953A1/en not_active Abandoned
2009
- 2009-12-22 JP JP2009291135A patent/JP2010106030A/ja active Pending

Also Published As

Publication number	Publication date
US7714003B2 (en)	2010-05-11
US20070238768A1 (en)	2007-10-11
US7772260B2 (en)	2010-08-10
JP2010106030A (ja)	2010-05-13
US7741349B2 (en)	2010-06-22
US20070088059A1 (en)	2007-04-19
WO2003051890A1 (en)	2003-06-26
US7230019B2 (en)	2007-06-12
DE60233350D1 (de)	2009-09-24
JP2005519882A (ja)	2005-07-07
ATE439363T1 (de)	2009-08-15
DK1463735T3 (da)	2009-12-14
ES2329882T3 (es)	2009-12-02
US20070265319A1 (en)	2007-11-15
AU2002350333A1 (en)	2003-06-30
US20090042953A1 (en)	2009-02-12
AU2002350333B2 (en)	2008-08-21
US7700635B2 (en)	2010-04-20
US20070238766A1 (en)	2007-10-11
US20050069492A1 (en)	2005-03-31
US20070021416A1 (en)	2007-01-25
CA2364985A1 (en)	2003-06-14
EP1463735B1 (en)	2009-08-12
US20070021476A1 (en)	2007-01-25
EP1463735A1 (en)	2004-10-06

Publication	Publication Date	Title
WO2002036562A3 (en)	2003-01-23	1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
GB0111186D0 (en)	2001-06-27	Novel compounds
EP1385937A4 (en)	2005-11-09	CONTRIBUTION OF POLYNUCLEOTIDE AGENTS TO THE CENTRAL NERVOUS SYSTEM
ATE439363T1 (de)	2009-08-15	Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides
TW200612905A (en)	2006-05-01	Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
BG108269A (en)	2004-12-30	Pyrazolopyrimidines as therapeutic agents
HK1038755A1 (zh)	2002-03-28	Tweak及tweak受体对抗物和使用对抗物治疗免疫失常症
AU2002361811A8 (en)	2003-07-09	1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
BG108268A (en)	2005-04-30	Pyrazolopyrimidines as therapeutic agents
TW200500344A (en)	2005-01-01	Novel compounds
MY147767A (en)	2013-01-31	Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MXPA04003668A (es)	2004-07-22	Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
MY142329A (en)	2010-11-15	Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents.
WO2002051837A3 (en)	2003-01-16	Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
TW200608979A (en)	2006-03-16	Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200800976A (en)	2008-01-01	New compounds for the treatment of neurological, psychiatric or pain disorders
PL358306A1 (en)	2004-08-09	Compounds with 5-ht1a activity useful for treating disorders of the outer retina
EP1392292A4 (en)	2004-08-11	PYRANOINDAZOLES AND THEIR USE IN GLAUCOMA TREATMENT
WO2002051832A3 (en)	2002-09-06	Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
WO2004074243A3 (en)	2004-12-02	Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
WO2003088748A8 (en)	2004-01-29	Use of heme oxygenase-1 and products of heme degradation
CA2474510A1 (en)	2003-09-04	Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
WO2002079169A8 (en)	2004-04-29	Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
BG108180A (en)	2004-09-30	Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
WO2003039453A3 (en)	2003-12-04	Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use